Trials / Completed
CompletedNCT00982865
Trial of MSC1936369B in Subjects With Solid Tumors
A Multicenter, Open Label, Phase I Trial of the MEK Inhibitor MSC1936369B Given Orally to Subjects With Solid Tumours
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 182 (actual)
- Sponsor
- Merck KGaA, Darmstadt, Germany · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a first in man trial with a primary objective being the determination of the Maximum Tolerated dose (MTD) and the dose-limiting toxicity (DLT) in several regimens of MEK inhibitor MSC1936369B administered orally once a day, in subjects with malignant solid tumors to see how safe is treatment with MSC1936369B.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MSC1936369B | |
| DRUG | MSC1936369B | |
| DRUG | MSC1936369B | |
| DRUG | MSC1936369B |
Timeline
- Start date
- 2007-12-31
- Primary completion
- 2013-03-31
- Completion
- 2016-04-30
- First posted
- 2009-09-23
- Last updated
- 2018-10-23
- Results posted
- 2018-10-23
Locations
9 sites across 4 countries: Australia, Belgium, France, Netherlands
Source: ClinicalTrials.gov record NCT00982865. Inclusion in this directory is not an endorsement.